BGG463
| Code | Size | Price |
|---|
| SYN-1226-M100 | 100 mg | Enquire |
Quantity:
| SYN-1226-M050 | 50 mg | Enquire |
Quantity:
| SYN-1226-M001 | 1 mg | £233.00 |
Quantity:
| SYN-1226-M005 | 5 mg | £467.00 |
Quantity:
| SYN-1226-M010 | 10 mg | £771.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Storage:
+4°C
Documents
Further Information
Alternate Names/Synonyms:
BGG-463
Appearance:
Solid.
CAS:
890129-26-7
EClass:
32160000
Form (Short):
liquid
InChi:
InChI=1S/C30H29F3N6O3/c1-19(40)36-27-16-28(35-18-34-27)42-23-8-9-24-20(14-23)4-3-5-25(24)29(41)37-22-7-6-21(26(15-22)30(31,32)33)17-39-12-10-38(2)11-13-39/h3-9,14-16,18H,10-13,17H2,1-2H3,(H,37,41)(H,34,35,36,40)
InChiKey:
MZZJNOOADWVFPD-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 890129-26-7. Formula: C30H29F3N6O3. MW: 578.6. BGG463 (NVP-BGG463) was generated by a rational 'hybrid design? approach. Like Imatinib, BGG463 disrupts the assembly of the hydrophobic spine, a characteristic feature of the active state of several kinases, thereby locking the kinase in an inactive 'DFG-out? conformation. BGG463 can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with a 50% inhibitory concentration (IC50) of 0.25 µM, 0.09 µM and 0.590 µM, respectively.
Molecular Formula:
C30H29F3N6O3
Molecular Weight:
578.6
Package Type:
Plastic Vial
Product Description:
BGG463 (NVP-BGG463) was generated by a rational 'hybrid design? approach. Like Imatinib, BGG463 disrupts the assembly of the hydrophobic spine, a characteristic feature of the active state of several kinases, thereby locking the kinase in an inactive 'DFG-out? conformation. BGG463 can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with a 50% inhibitory concentration (IC50) of 0.25 µM, 0.09 µM and 0.590 µM, respectively.
Purity:
>95% (HPLC)
Solubility Chemicals:
Soluble in DMSO.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Rational design of T315I BCR-Abl inhibitors for the treatment of drug-resistant chronic myelogenous leukemia (CML): BGG463: P.W. Manley, et al.; Chimia (Aarau) 62, 579 (2008)
Related Products
| Product Name | Product Code | Supplier |
|---|